Item 4.01 Change in Registrant’s Certifying Accountant.
On June 20, 2023, the Board of Directors of GlobeStar Therapeutics Corporation,
a Wyoming corporation (the “Company”), approved the engagement of Fruci & Associates II, PLLC (“F&A”)
as the Company’s independent registered public accounting firm for the Company’s fiscal year ending September 30, 2023, effective
immediately, and dismissed M&K CPAS, PLLC (“M&K”) as the Company’s independent registered public accounting
firm.
During the Company’s two most recent fiscal years ended September
30, 2022 and 2021 and the subsequent interim period, there were no (i) no disagreements (as defined in item 304(a)(1)(iv) of Regulation
S-K) with M&K on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure,
which disagreements, if not resolved to the satisfaction of M&K, would have caused M&K to make reference to the subject matter
of the disagreements in their report on the Company’s financial statements, or (ii) reportable events under Item 304(a)(1)(v) of
Registration S-K).
The audit reports of M&K on the consolidated financial statements of
the Company as of and for the years ended September 30, 2022 and 2021 did not contain an adverse opinion or a disclaimer of opinion, and
were not qualified or modified as to uncertainty, audit scope or accounting principles, except as follows:
M&K’s report for the Company’s financial statements for
the fiscal years ended September 30, 2021 and 2022 contained an explanatory paragraph in respect to the Company’s ability to continue
as a going concern.
The Company previously provided M&K with a copy of the disclosures
contained in this Item 4.01(a). The Company has requested that M&K issue a letter, addressed to the U.S. Securities and Exchange Commission,
stating whether M&K agrees with the statements contained in this Item 4.01(a). A copy of the letter received from M&K, dated June
27, 2023, is filed as Exhibit 16.1 to this Form 8-K.
During the fiscal years ended September
30, 2022 and 2021 and any subsequent interim period through June 20, 2023, neither the Company nor anyone on its behalf consulted with
F&A regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed; (ii) the type
of audit opinion that might be rendered on its financial statements by F&A, and neither a written report or oral advice was provided
to the Company by F&A that F&A concluded was an important factor considered by the Company in reaching a decision as to any accounting,
auditing or financial reporting issues; or (iii) any other matter that was the subject of a “disagreement” or “reportable
event” (as such terms are described in Items 304(a)(1)(iv) and (v), respectively, of Regulation S-K) between the Company and its
former independent registered public accounting firm, M&K.